{
    "clinical_study": {
        "@rank": "56838", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This prospective, multicenter observational study will evaluate the efficacy, safety and\n      tolerability of Tarceva (erlotinib) as second-line treatment in patients with locally\n      advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed after\n      pemetrexed-containing first-line chemotherapy. Eligible patients will be followed until\n      withdrawal of consent, lost-to-follow-up or study termination, whichever occurs first."
        }, 
        "brief_title": "An Observational Study of Tarceva as Second-Line Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Pemetrexed in First-Line (TIME)", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Histologically or cytologically documented locally advanced or metastatic non-small\n             cell lung cancer (inoperable stage III or IV according to 7th TNM classification)\n\n          -  Experiencing disease progression after pemetrexed-containing first-line chemotherapy\n             regimen\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n\n          -  Initiated on second-line treatment with Tarceva at the most 4 weeks prior to study\n             entry at baseline (date of signature of informed consent)\n\n        Exclusion Criteria:\n\n          -  Prior chemotherapy/targeted therapy after disease progression after first-line\n             treatment in the advanced NSCLC setting\n\n          -  Contraindication for Tarceva according to the Summary of Product characteristics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with locally advanced or metastatic non-small cell lung cancer initiated on\n        second-line Tarceva therapy after first-line pemetrexed-containing chemotherapy"
            }
        }, 
        "enrollment": {
            "#text": "59", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01664533", 
            "org_study_id": "ML25708"
        }, 
        "intervention_browse": {
            "mesh_term": "Pemetrexed"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aalst", 
                        "country": "Belgium", 
                        "zip": "9300"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Antwerpen", 
                        "country": "Belgium", 
                        "zip": "2020"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boussu", 
                        "country": "Belgium", 
                        "zip": "7360"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium", 
                        "zip": "1200"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleroi", 
                        "country": "Belgium", 
                        "zip": "6000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dendermonde", 
                        "country": "Belgium", 
                        "zip": "9200"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duffel", 
                        "country": "Belgium", 
                        "zip": "2570"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium", 
                        "zip": "2650"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frameries", 
                        "country": "Belgium", 
                        "zip": "7080"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genk", 
                        "country": "Belgium", 
                        "zip": "3600"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gilly", 
                        "country": "Belgium", 
                        "zip": "6060"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gosselies", 
                        "country": "Belgium", 
                        "zip": "6041"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liege", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mons", 
                        "country": "Belgium", 
                        "zip": "7000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montegn\u00e9e", 
                        "country": "Belgium", 
                        "zip": "4420"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Namur", 
                        "country": "Belgium", 
                        "zip": "5000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottignies", 
                        "country": "Belgium", 
                        "zip": "1340"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roeselare", 
                        "country": "Belgium", 
                        "zip": "8800"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sint Niklaas", 
                        "country": "Belgium", 
                        "zip": "9100"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tournai", 
                        "country": "Belgium", 
                        "zip": "7500"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Turnhout", 
                        "country": "Belgium", 
                        "zip": "2300"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prospective, Open-label, Multicenter, National, Non-interventional Phase IV Trial of the Effectiveness, Safety and Tolerability of Tarceva as Second-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC), After Failure of First-line Treatment With a Pemetrexed-containing Chemotherapy Regimen", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "approximately 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01664533"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Best overall response (tumor assessments according to RECIST or other criteria)", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Best confirmed overall response", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}